We read with great interest the paper by Panes et al1 regarding the efficacy of early azathioprine (AZA) therapy in early Crohn’s disease (CD). The “AZathioprine for Treatment or Early Crohn’s disease in adults” (AZTEC) study was an investigator-initiated, multicenter, randomized, double-blind, placebo-controlled trial conducted in 31 Spanish hospitals over 3 years. The authors developed a randomized placebo-controlled trial in very early CD patients (<8 weeks of diagnosis) without bowel damage (symptomatic stenotic, penetrating, or perianal disease).